DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Rivastigmine tartrateis the generic ingredient in two branded drugs marketed by Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orchid Hlthcare, Sun Pharm, and Watson Labs, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.
There are thirty-two drug master file entries for rivastigmine tartrate. Twelve suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for rivastigmine tartrate
Recent Clinical Trials for rivastigmine tartrate
Identify potential brand extensions & 505(b)(2) entrants
|Taishoff Family Foundation||Phase 1/Phase 2|
|Duke University||Phase 1/Phase 2|
|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||Phase 1/Phase 2|
Generic filers with tentative approvals for RIVASTIGMINE TARTRATE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for rivastigmine tartrate
|Drug Class||Cholinesterase Inhibitor |
|Mechanism of Action||Cholinesterase Inhibitors |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Sun Pharm||RIVASTIGMINE TARTRATE||rivastigmine tartrate||CAPSULE;ORAL||077131-002||Oct 22, 2007||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|Aurobindo Pharma Ltd||RIVASTIGMINE TARTRATE||rivastigmine tartrate||CAPSULE;ORAL||204572-004||Mar 25, 2016||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|Orchid Hlthcare||RIVASTIGMINE TARTRATE||rivastigmine tartrate||CAPSULE;ORAL||090879-001||Jun 10, 2015||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Novartis||EXELON||rivastigmine tartrate||CAPSULE;ORAL||020823-005||Apr 21, 2000||Start Trial||Start Trial|
|Novartis||EXELON||rivastigmine tartrate||CAPSULE;ORAL||020823-003||Apr 21, 2000||Start Trial||Start Trial|
|Novartis||EXELON||rivastigmine tartrate||CAPSULE;ORAL||020823-004||Apr 21, 2000||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.